[Eli Lilly and Company](https://www.lillyinvestigatorresearch.com)

June 15, 2026: Application due date

Support includes provision of study drug and/or financial support; award size and duration vary by project scope.

Supports Canadian investigator-initiated research on real-world effectiveness of mirkizumab in IBD and the epidemiology of overweight/obese individuals with IBD.

--- ## Description This grant opportunity, offered by Eli Lilly and Company, seeks investigator-initiated research proposals from Canadian researchers focused on two main areas: (1) evaluating the real-world effectiveness of mirkizumab in patients with Inflammatory Bowel Disease (IBD) under routine clinical practice conditions, and (2) analyzing the epidemiology, burden, and disease-state factors among overweight and/or obese individuals living with IBD in Canada. Proposals may address one or both areas, either as integrated or separate studies, and should align with the scientific objectives outlined in the official RFP. The grantee is responsible for study design, conduct, and regulatory compliance. Lilly will provide study drug and/or financial support for selected proposals and oversee the review process. --- ## Due Dates - June 15, 2026: Application due date (submit completed proposal form to CCRG@lilly.com) --- ## Funding Amount - Funding may include study drug and/or financial support. - Award size and duration are determined based on the proposed project’s scope and requirements as specified in the RFP and proposal form. --- ## Eligibility - Open to researchers and research teams based in Canada. - Projects must be externally initiated, designed, and sponsored (not Lilly-sponsored trials). - The applicant must be able to assume regulatory sponsorship responsibilities and conduct the study in accordance with ethical, regulatory, and good clinical practice requirements. - Research must align with one or both of the following focus areas: - Real-world effectiveness of mirkizumab in IBD. - Epidemiology of overweight and/or obese individuals living with IBD in Canada. --- ## Application Process 1. **Obtain Materials:** Access the RFP PDF and download the official proposal form from the [Lilly Competitive Grants page](https://www.lillyinvestigatorresearch.com/competitive-grants#request-for-proposals-efficacy-of-lebrikizumab-in-patients-with-fibrosing-skin-c). 2. **Prepare Proposal:** Complete the proposal form, ensuring your research addresses the priority areas and follows the structure/instructions in the RFP and form. 3. **Submit Proposal:** Email the completed proposal form to [CCRG@lilly.com](mailto:CCRG@lilly.com) by June 15, 2026. 4. **Review:** Proposals will be reviewed by Lilly’s internal medical/scientific committees, with possible external committee involvement for final selection. --- ## Additional Information - The grantee is fully responsible for study design, conduct, and regulatory compliance. - Detailed eligibility, budget, and evaluation criteria are provided in the official RFP PDF and proposal form. - Late submissions may not be considered. --- ## External Links - [Eli Lilly Investigator Research Home](https://www.lillyinvestigatorresearch.com) - [Competitive Grants Page (RFP & Forms)](https://www.lillyinvestigatorresearch.com/competitive-grants#request-for-proposals-efficacy-of-lebrikizumab-in-patients-with-fibrosing-skin-c) - [Frequently Asked Questions](https://www.lillyinvestigatorresearch.com/FAQs) --- ## Contact Information | Purpose | Contact | |------------------------|-------------------------------------------| | Proposal Submission | [CCRG@lilly.com](mailto:CCRG@lilly.com) | | General Inquiries/FAQs | [Help & FAQs](https://www.lillyinvestigatorresearch.com/FAQs) |

Request for Proposals in Canada: Real-world effectiveness of mirkizumab in IBD and disease-state epidemiology in overweight and/or obese individuals living with IBD in Canada

Sign in to see full grant listing